Adjusted and unadjusted ORs for risk factors in predicting 30 day AKI associated mortality
| . | Unadjusted . | Adjusteda . | ||
|---|---|---|---|---|
| . | OR (95% CI) . | P . | OR (95% CI) . | P . |
| Total number of episodes | ||||
| 1 | Reference | – | – | – |
| 2 | 1.38 (1.33–1.43) | 0.000 | 1.33 (1.28–1.38) | 0.000 |
| 3 | 1.50 (1.41–1.59) | 0.000 | 1.53 (1.44–1.63) | 0.000 |
| ≥4 | 1.18 (1.10–1.28) | 0.000 | 1.37 (1.27–1.48) | 0.000 |
| Gender | ||||
| Female | Reference | – | – | – |
| Male | 1.28 (1.25–1.32) | 0.000 | – | – |
| Pre-existing CKD | ||||
| No | Reference | – | – | – |
| Yes | 1.10 (1.07–1.14) | 0.000 | – | – |
| AKI stage of index episode | ||||
| Stage 1 | Reference | – | – | – |
| Stage 2 | 1.77 (1.71–1.84) | 0.000 | – | – |
| Stage 3 | 1.91 (1.82–2.01) | 0.000 | – | – |
| AKI type of index episode | ||||
| CA | Reference | – | – | – |
| HA | 1.61 (1.55–1.66) | 0.000 | – | – |
| Age at index episode, years | 1.04 (1.04–1.04) | 0.000 | – | – |
| . | Unadjusted . | Adjusteda . | ||
|---|---|---|---|---|
| . | OR (95% CI) . | P . | OR (95% CI) . | P . |
| Total number of episodes | ||||
| 1 | Reference | – | – | – |
| 2 | 1.38 (1.33–1.43) | 0.000 | 1.33 (1.28–1.38) | 0.000 |
| 3 | 1.50 (1.41–1.59) | 0.000 | 1.53 (1.44–1.63) | 0.000 |
| ≥4 | 1.18 (1.10–1.28) | 0.000 | 1.37 (1.27–1.48) | 0.000 |
| Gender | ||||
| Female | Reference | – | – | – |
| Male | 1.28 (1.25–1.32) | 0.000 | – | – |
| Pre-existing CKD | ||||
| No | Reference | – | – | – |
| Yes | 1.10 (1.07–1.14) | 0.000 | – | – |
| AKI stage of index episode | ||||
| Stage 1 | Reference | – | – | – |
| Stage 2 | 1.77 (1.71–1.84) | 0.000 | – | – |
| Stage 3 | 1.91 (1.82–2.01) | 0.000 | – | – |
| AKI type of index episode | ||||
| CA | Reference | – | – | – |
| HA | 1.61 (1.55–1.66) | 0.000 | – | – |
| Age at index episode, years | 1.04 (1.04–1.04) | 0.000 | – | – |
Adjusted for sex, pre-existing CKD, AKI stage of index episode, AKI type of index episode and age at index episode.
CI, confidence interval.
Adjusted and unadjusted ORs for risk factors in predicting 30 day AKI associated mortality
| . | Unadjusted . | Adjusteda . | ||
|---|---|---|---|---|
| . | OR (95% CI) . | P . | OR (95% CI) . | P . |
| Total number of episodes | ||||
| 1 | Reference | – | – | – |
| 2 | 1.38 (1.33–1.43) | 0.000 | 1.33 (1.28–1.38) | 0.000 |
| 3 | 1.50 (1.41–1.59) | 0.000 | 1.53 (1.44–1.63) | 0.000 |
| ≥4 | 1.18 (1.10–1.28) | 0.000 | 1.37 (1.27–1.48) | 0.000 |
| Gender | ||||
| Female | Reference | – | – | – |
| Male | 1.28 (1.25–1.32) | 0.000 | – | – |
| Pre-existing CKD | ||||
| No | Reference | – | – | – |
| Yes | 1.10 (1.07–1.14) | 0.000 | – | – |
| AKI stage of index episode | ||||
| Stage 1 | Reference | – | – | – |
| Stage 2 | 1.77 (1.71–1.84) | 0.000 | – | – |
| Stage 3 | 1.91 (1.82–2.01) | 0.000 | – | – |
| AKI type of index episode | ||||
| CA | Reference | – | – | – |
| HA | 1.61 (1.55–1.66) | 0.000 | – | – |
| Age at index episode, years | 1.04 (1.04–1.04) | 0.000 | – | – |
| . | Unadjusted . | Adjusteda . | ||
|---|---|---|---|---|
| . | OR (95% CI) . | P . | OR (95% CI) . | P . |
| Total number of episodes | ||||
| 1 | Reference | – | – | – |
| 2 | 1.38 (1.33–1.43) | 0.000 | 1.33 (1.28–1.38) | 0.000 |
| 3 | 1.50 (1.41–1.59) | 0.000 | 1.53 (1.44–1.63) | 0.000 |
| ≥4 | 1.18 (1.10–1.28) | 0.000 | 1.37 (1.27–1.48) | 0.000 |
| Gender | ||||
| Female | Reference | – | – | – |
| Male | 1.28 (1.25–1.32) | 0.000 | – | – |
| Pre-existing CKD | ||||
| No | Reference | – | – | – |
| Yes | 1.10 (1.07–1.14) | 0.000 | – | – |
| AKI stage of index episode | ||||
| Stage 1 | Reference | – | – | – |
| Stage 2 | 1.77 (1.71–1.84) | 0.000 | – | – |
| Stage 3 | 1.91 (1.82–2.01) | 0.000 | – | – |
| AKI type of index episode | ||||
| CA | Reference | – | – | – |
| HA | 1.61 (1.55–1.66) | 0.000 | – | – |
| Age at index episode, years | 1.04 (1.04–1.04) | 0.000 | – | – |
Adjusted for sex, pre-existing CKD, AKI stage of index episode, AKI type of index episode and age at index episode.
CI, confidence interval.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
